RhumbLine Advisers
WHWK

RhumbLine Advisers’s Whitehawk Therapeutics WHWK Stock Holding History

RhumbLine Advisers’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Buy
+24,529
New +$102K ﹤0.01% 3487
2024
Q3 		– Sell
-9,487
Closed -$13.8K – 4356
2024
Q2 		$13.8K Sell
9,487
-15,899
-63% -$29.5K ﹤0.01% 3933
2024
Q1 		$59.4K Buy
25,386
+589
+2% +$1.14K ﹤0.01% 3591
2023
Q4 		$50.1K Hold
24,797
– – ﹤0.01% 3633
2023
Q3 		$120K Buy
24,797
+1,249
+5% +$7.26K ﹤0.01% 3396
2023
Q2 		$161K Buy
23,548
+4,245
+22% +$33K ﹤0.01% 3345
2023
Q1 		$140K Buy
19,303
+814
+4% +$8.7K ﹤0.01% 2812
2022
Q4 		$237K Buy
18,489
+424
+2% +$5.54K ﹤0.01% 2748
2022
Q3 		$255K Buy
18,065
+1,069
+6% +$14K ﹤0.01% 2802
2022
Q2 		$209K Buy
+16,996
New +$252K ﹤0.01% 2914

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's WHWK Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Whitehawk Therapeutics (WHWK) in Q2 2026: 24,529 shares worth $112K. The stake represents ﹤0.01% of the portfolio and ranks #3487 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in WHWK as recently as Q2 2024.

RhumbLine Advisers first reported a position in WHWK in Q2 2022 and has held it in 10 quarters since. The position peaked at $255K in Q3 2022. 78 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • RhumbLine Advisers held 24,529 shares of Whitehawk Therapeutics worth $112K as of Q2 2026.
  • Whitehawk Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • Whitehawk Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3487 holding.
  • RhumbLine Advisers first reported a position in Whitehawk Therapeutics in Q2 2022 and has held it in 10 quarters since.
  • RhumbLine Advisers's Whitehawk Therapeutics position peaked at $255K in Q3 2022.
  • 78 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.